Maravai LifeSciences (MRVI): Price and Financial Metrics
MRVI Price/Volume Stats
| Current price | $13.76 | 52-week high | $33.42 |
| Prev. close | $13.33 | 52-week low | $11.59 |
| Day low | $13.25 | Volume | 2,964,600 |
| Day high | $13.95 | Avg. volume | 2,031,135 |
| 50-day MA | $13.59 | Dividend yield | N/A |
| 200-day MA | $16.02 | Market Cap | 3.45B |
MRVI Stock Price Chart Interactive Chart >
MRVI POWR Grades
- MRVI scores best on the Quality dimension, with a Quality rank ahead of 90.55% of US stocks.
- MRVI's strongest trending metric is Growth; it's been moving down over the last 179 days.
- MRVI ranks lowest in Growth; there it ranks in the 0th percentile.
MRVI Stock Summary
- MARAVAI LIFESCIENCES HOLDINGS INC's stock had its IPO on November 20, 2020, making it an older stock than merely 11.68% of US equities in our set.
- With a price/sales ratio of 4.69, MARAVAI LIFESCIENCES HOLDINGS INC has a higher such ratio than 77.65% of stocks in our set.
- As for revenue growth, note that MRVI's revenue has grown -19.84% over the past 12 months; that beats the revenue growth of only 11.46% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to MARAVAI LIFESCIENCES HOLDINGS INC, a group of peers worth examining would be CLS, LPRO, UTRS, OPEN, and STIM.
- MRVI's SEC filings can be seen here. And to visit MARAVAI LIFESCIENCES HOLDINGS INC's official web site, go to www.maravai.com.
MRVI Valuation Summary
- MRVI's price/sales ratio is 4.8; this is 118.18% higher than that of the median Healthcare stock.
- Over the past 30 months, MRVI's price/earnings ratio has gone up 1744.1.
Below are key valuation metrics over time for MRVI.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| MRVI | 2023-05-23 | 4.8 | 6.6 | 22.3 | 15.1 |
| MRVI | 2023-05-22 | 4.8 | 6.5 | 22.3 | 15.1 |
| MRVI | 2023-05-19 | 4.7 | 6.4 | 21.9 | 14.8 |
| MRVI | 2023-05-18 | 4.5 | 6.1 | 20.9 | 14.1 |
| MRVI | 2023-05-17 | 4.5 | 6.2 | 21.0 | 14.2 |
| MRVI | 2023-05-16 | 4.7 | 6.4 | 21.9 | 14.9 |
MRVI's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- MRVI has a Quality Grade of C, ranking ahead of 71.9% of graded US stocks.
- MRVI's asset turnover comes in at 0.307 -- ranking 150th of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows MRVI's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2020-12-31 | 0.307 | 0.72 | 0.155 |
MRVI Price Target
For more insight on analysts targets of MRVI, see our MRVI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $49.33 | Average Broker Recommendation | 1.22 (Strong Buy) |
Maravai LifeSciences (MRVI) Company Bio
Maravai Lifesciences Holdings, Inc. operates as an investment holding company. It develops biopharmaceuticals. The company is headquartered in San Diego, CA.
Latest MRVI News From Around the Web
Below are the latest news stories about MARAVAI LIFESCIENCES HOLDINGS INC that investors may wish to consider to help them evaluate MRVI as an investment opportunity.
TriLink BioTechnologies® Announces Manufacturing Capabilities Expansion as mRNA Manufacturing Facility Nears CompletionSAN DIEGO, May 24, 2023--TriLink BioTechnologies® Announces Manufacturing Capabilities Expansion as mRNA Manufacturing Facility Nears Completion |
Q1 2023 Maravai LifeSciences Holdings Inc Earnings CallQ1 2023 Maravai LifeSciences Holdings Inc Earnings Call |
TriLink BioTechnologies Introduces Latest mRNA Capping Technology: CleanCap® M6 analogNewest cap analog product improves mRNA potency with greater protein expression, offers time and cost savings, and streamlines manufacturing to drive critical therapeutic and vaccine developmentSAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- TriLink BioTechnologies (TriLink), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has launched its newest cap analog, CleanCap® M6 . The latest CleanCap analog is expected to help developers and researche |
Maravai LifeSciences (MRVI) Q1 2023 Earnings Call TranscriptDeb Hart, head of investor relations, you may begin your conference. Trey Martin, president of our biologic safety testing; Drew Burch, executive vice president, nucleic acid products; and Becky Buzzeo, our chief commercial officer, will join the call for the question-and-answer session following the prepared remarks. |
Maravai LifeSciences Holdings, Inc. (MRVI) Lags Q1 Earnings and Revenue EstimatesMaravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of -25% and 0.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? |
MRVI Price Returns
| 1-mo | -4.91% |
| 3-mo | -11.62% |
| 6-mo | 3.46% |
| 1-year | -56.96% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -3.84% |
| 2022 | -65.85% |
| 2021 | 49.38% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...